Healthcare
ByHow Does AstraZeneca Transform ADC Dominance Into an $80 Billion Revenue Juggernaut by 2030?
AstraZeneca masterminds an “oncology everywhere” empire through surgical deployment of 20+ late-stage novel molecular entities across oncology (43% revenue), CVRM,…
How Does Roche’s TA-Wise Fortress Strategy Conquer 2030 LOE Cliffs Amid Obesity Wars?
Roche orchestrates a pharma-diagnostics juggernaut, surgically allocating 60% of R&D across five therapeutic arenas while weaponizing FoundationOne/Flatiron (covering 60% of pipeline…
What Drives Novartis’ Pipeline Dominance Through 2030?
Novartis’ clinical pipeline exemplifies a “focus factory” strategy, ruthlessly prioritizing 30+ high-ROI NMEs across five core areas (immunology,…
Is CMS’s Block on Elevance MA Sign‑Ups a Turning Point for Payer Compliance?
The Centers for Medicare & Medicaid Services (CMS) has halted new Medicare Advantage enrollments for Elevance Health, freezing sign‑ups for…
Indian Biopharma Faces Freight Surge Amid US-Iran Escalation
India’s biopharma sector confronts $300-500M export losses as US-Iran war disrupts Gulf shipping, spiking container surcharges to $3,500–$5,000…
What broader implications does Zealand Pharma’s petrelintide trial setback raise for the GLP-1 obesity market?
Trial Context Recap ZUPREME-1 delivered 10.7% peak weight loss over 42 weeks across 493 patients, surpassing placebo but…
